[Form 4] CYTOKINETICS INC Insider Trading Activity

Q: How many CYTOKINETICS (CYTK) shares did John T. Henderson sell and at what price?

He sold 20,000 shares of Cytokinetics Common Stock in an open-market transaction at $75.97 per share. This sale occurred on the same date as his option exercise and reduced, but did not eliminate, his overall direct share position in the company.

Q: What options did John T. Henderson exercise in this CYTK Form 4 filing?

He exercised a non-qualified stock option covering 20,000 shares of Cytokinetics Common Stock at a $7.61 exercise price. Following the exercise, the option position was fully used, with 0 derivative securities remaining under that specific grant according to the filing data.

Q: How many CYTOKINETICS (CYTK) shares does John T. Henderson hold after these transactions?

After the reported transactions, he holds 75,237 Cytokinetics Common Stock shares directly and 83 shares indirectly through his spouse. These figures show his ongoing equity stake in the company following the option exercise and same-day open-market share sale.

Q: Does John T. Henderson still have Cytokinetics stock options after this Form 4?

The filing shows a non-qualified stock option for 20,000 shares exercised in full, leaving 0 derivative securities under that grant. The derivative summary is empty, indicating no remaining option balance from this particular option award after the reported exercise.

Cytokinetics director John T. Henderson reported an option exercise and related share sale.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cytokinetics director John T. Henderson reported an option exercise and related share sale. He exercised non-qualified stock options for 20,000 shares of Common Stock at $7.61 per share and, on the same date, sold 20,000 shares in an open-market transaction at $75.97 per share.

After these transactions, he held 75,237 shares of Common Stock directly and 83 shares indirectly through his spouse. The option grant covering 20,000 shares was fully exercised, leaving no remaining balance under that option.

Insider Trade Summary 10b5-1

Exercise and Sale: 20,000 shares ($1.37M approx. pre-tax spread)

Exercise and Sale 4 txns

Insider HENDERSON JOHN T

Role Director

Sold 20,000 shs ($1.52M)

Approx. gross sale proceeds $1.52M

Approx. exercise cost $152K

Approx. pre-tax spread $1.37M

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	20,000	$0.00	$0.00
Exercise	Common Stock	20,000	$7.61	$152K
Sale	Common Stock	20,000	$75.97	$1.52M
holding	Common Stock	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 75,237 shares (Direct); Common Stock — 83 shares (Indirect, by Spouse)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYTOKINETICS (CYTK) director John T. Henderson report?

John T. Henderson reported exercising options for 20,000 Cytokinetics shares at $7.61 each and selling 20,000 shares at $75.97 per share. This reflects an exercise-and-sell pattern, converting an option position into cash while retaining a sizable remaining shareholding.

How many CYTOKINETICS (CYTK) shares did John T. Henderson sell and at what price?

He sold 20,000 shares of Cytokinetics Common Stock in an open-market transaction at $75.97 per share. This sale occurred on the same date as his option exercise and reduced, but did not eliminate, his overall direct share position in the company.

What options did John T. Henderson exercise in this CYTK Form 4 filing?

He exercised a non-qualified stock option covering 20,000 shares of Cytokinetics Common Stock at a $7.61 exercise price. Following the exercise, the option position was fully used, with 0 derivative securities remaining under that specific grant according to the filing data.

How many CYTOKINETICS (CYTK) shares does John T. Henderson hold after these transactions?

After the reported transactions, he holds 75,237 Cytokinetics Common Stock shares directly and 83 shares indirectly through his spouse. These figures show his ongoing equity stake in the company following the option exercise and same-day open-market share sale.

Does John T. Henderson still have Cytokinetics stock options after this Form 4?

The filing shows a non-qualified stock option for 20,000 shares exercised in full, leaving 0 derivative securities under that grant. The derivative summary is empty, indicating no remaining option balance from this particular option award after the reported exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/05/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENDERSON JOHN T

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/05/2026		M		20,000	A	$7.61	95,237	D
Common Stock	05/05/2026		S		20,000	D	$75.97	75,237	D
Common Stock								83	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (Right to Buy)	$7.61	05/05/2026		M			20,000	06/18/2016	05/18/2026	Common Stock	20,000	$0	0	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Henderson	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR